BridgeMD
New treatment option for Ischemic Stroke
Official title Verapamil for Neuroprotection in Stroke
ClinicalTrials.gov ID: NCT03347786
What this study is testing
What is 10 mg Intra-arterial Verapamil?
10 mg Intra-arterial Verapamil is an investigational medicine, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Written informed consent
- 18 years of age and over
- Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
- Candidate for mechanical thrombectomy procedure
- Onset of symptoms less than 8 hours
You likely can't join if
- Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
- Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
- Thrombocytopenia (platelet count \<75,000/mm3)
- History of intolerance to verapamil
- Previous functional disability (modified Rankin \> 1)
- Severe stroke (NIHSS\>22)
See the full eligibility criteria
- Written informed consent
- 18 years of age and over
- Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
- Candidate for mechanical thrombectomy procedure
- Onset of symptoms less than 8 hours
- Measurable neurologic deficit (NIHSS ≥4)
- Willingness to follow up with rehabilitation therapy
- Anticipated life expectancy of at least 3 months
- Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
- Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
- Thrombocytopenia (platelet count \<75,000/mm3)
- History of intolerance to verapamil
- Previous functional disability (modified Rankin \> 1)
- Severe stroke (NIHSS\>22)
- Stuporous or comatose
- Unlikely to be available for 90 day follow-up
The study team makes the final eligibility decision.
Where it's taking place
- Atlantic City, New Jersey, United States
- Langhorne, Pennsylvania, United States
- Upland, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Atlantic City, New Jersey, United States; Langhorne, Pennsylvania, United States; Upland, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.